ROR gamma T inhibitors (Amgen/Almirall)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameROR gamma T inhibitors (Amgen/Almirall)
Drug Alias NameROR gamma T inhibitors (Nuevolution/Almirall)RORgT inhibitors (Nuevolution)ROR gamma T inhibitors (Nuevolution)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNuclear receptor ROR-gamma antagonists
TargetsNuclear receptor ROR-gamma
Therapy Area/IndicationsInflammationImmune System DiseasesInflammatory Bowel Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesDenmarkSpain
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNuevolution AS
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNuevolution ASAmgen IncAlmirall Sa
Active IndicationsN/A
Inactive IndicationsInflammationImmune System DiseasesInflammatory Bowel Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A